Sygnature Discovery and DaltonTx Collaborate to Advance AI-Enabled Decision-Making Across CRO Drug Discovery Programs

• Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, has announced a strategic collaboration with DaltonTx, an AI technology company, to integrate DaltonTx’s Dalton platform into Sygnature’s computational and medicinal chemistry toolkit — with the goal of accelerating decision-making and reducing synthesis burden across discovery programs.

• The collaboration integrates Dalton alongside existing AI platforms including SygDesign, BullFrog AI, and Iktos, and includes a retrospective validation study using a legacy oncology program focused on a small molecule clinical candidate currently in Phase I development, assessing whether Dalton could have enabled earlier, more efficient candidate selection.

Sygnature Discovery, a leading integrated drug discovery CRO, has announced a strategic collaboration with DaltonTx, an AI technology company, to integrate DaltonTx’s Dalton platform into Sygnature’s existing computational and medicinal chemistry workflows. Announced on June 4, 2026, from Nottingham, UK, the collaboration is designed to accelerate medicinal chemistry decision-making across drug discovery programs while addressing growing industry concerns around the secure handling of proprietary customer data in AI-enabled environments.

The Dalton platform combines a secure and scalable backend architecture with a natural language interface powered by agentic AI technologies, enabling scientists to drive ideation, hypothesis generation, and problem-solving through conversational workflows. Unlike standalone AI applications, Dalton integrates data, models, and experimental results into a unified, continuously learning environment — capturing what worked, what failed, and why across each program cycle with full context. Sygnature is integrating Dalton alongside its existing AI toolkit, which includes SygDesign, BullFrog AI, and Iktos, to create a complementary multi-platform environment for computational and medicinal chemistry decision support.

For CRO clients outsourcing drug discovery programs, the practical impact of the collaboration is intended to be measurable. By embedding AI-driven decision support earlier in the design-make-test-analyze cycle, Sygnature aims to reduce the number of compounds that need to be synthesized and tested, shorten DMTA cycles, and accelerate progression toward candidate selection. To validate these claims in a real-world context, the collaboration includes a retrospective evaluation using a legacy oncology program centered on a small molecule clinical candidate currently in Phase I development — assessing whether the Dalton platform could have enabled earlier candidate selection through improved decision-making and a reduced synthesis burden.

Data security is an explicit design requirement of the collaboration. Sygnature has ensured that customer data and AI models are compartmentalized on a per-program basis, so that no customer’s proprietary information is used to train models supporting other projects. This architecture directly addresses one of the most significant barriers to AI adoption in outsourced drug discovery settings, where sponsors require assurance that competitive intelligence embedded in their discovery data cannot be accessed or leveraged across program boundaries.

“AI in drug discovery continues to evolve rapidly, but we believe the future lies in combining the power of machine learning with the expertise and intuition of experienced scientists. By helping scientists make better-informed decisions earlier in the discovery process, we can reduce the number of compounds synthesized and tested, shorten DMTA cycles, and accelerate progression toward candidate selection.”

Simon Hirst, Chief Executive Officer, Sygnature Discovery